医学
医学物理学
放射肿瘤学
佣金
术语
放射免疫疗法
核医学
放射治疗
内科学
财务
语言学
哲学
抗体
经济
免疫学
单克隆抗体
作者
Paul E. Wallner,Don C. Yoo,Jérémie Calais,Freddy E. Escorcia,Carina Marí Aparici,Jeff M. Michalski,Michael J. Morris,Zachary S. Morris,Daniel A. Pryma,B.M. Rabatic,Navesh Sharma,Neha Vapiwala,Munir Ghesani,Rathan M. Subramaniam,William Small,Naomi R. Schechter
标识
DOI:10.1097/coc.0000000000001072
摘要
Objectives: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology, and the Society of Nuclear Medicine and Molecular Imaging. The document is intended to serve as a resource for appropriately trained and licensed physicians who perform therapeutic procedures with unsealed sources, referred to in the document using the more inclusive terminology of radiopharmaceuticals, for which a written directive is required for authorized users under NRC 10 CFR 35.300. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the American Radium Society. Results: This practice parameter addresses the overall role of the applicable physician-authorized user, Qualified Medical Physicist, and other specialized personnel involved in the delivery of radiopharmaceutical therapy. Therapeutic radiopharmaceuticals include those administered as elemental radioactive isotopes (radionuclides) or the radioactive element incorporated into a targeting molecule (ligand) by one or more chemical bonds. This document provides guidance regarding general principles of radionuclide therapies and indications of various alpha, beta, gamma, and mixed emission agents with references to several recent practice parameters on new and commonly performed radiopharmaceutical therapies. Conclusions: This document addresses clinical circumstances, elements of available agents, and the qualifications and responsibilities of various members of the radiation care team, specifications of consultation and other clinical documentation, post-therapy follow-up, radiation safety precautions, elements of quality control and improvement programs, infection control, and patient education to ensure optimal patient care and safety when utilizing radiopharmaceuticals.
科研通智能强力驱动
Strongly Powered by AbleSci AI